Physician profile
Jaime Baynes-Fields
NPI 1376978866
$7,143.54
in general payments reported to CMS, 2019-2025
33 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $17.50 · 2021: $360 · 2022: $1,385 · 2023: $2,659 · 2024: $821 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,937 · Consulting Fee: $1,688 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,936.78 |
| Consulting Fee | $1,688.00 |
| Education | $165.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $2,133.75 | 2021-2025 | |
| Vifor Pharma, INC. | $724.97 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $537.98 | 2020-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $491.48 | 2022-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $430.13 | 2021-2025 | Jynarque |
| Amgen INC. | $389.27 | 2022-2025 | Tavneos, Parsabiv, Aranesp |
| Mallinckrodt Hospital Products INC. | $285.32 | 2021-2025 | Terlivaz, Acthar |
| Ani Pharmaceuticals, INC. | $234.68 | 2022-2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $214.15 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $204.80 | 2025 | |
| Opko Pharmaceuticals, LLC | $161.45 | 2025 | Rayaldee |
| Akebia Therapeutics INC | $156.56 | 2021-2025 | Auryxia, Vafseo |
| Astrazeneca Uk Limited | $124.99 | 2023 | |
| Glaxosmithkline, LLC. | $116.23 | 2022-2024 | Benlysta, Jesduvroq |
| Baxter Healthcare | $99.13 | 2022-2024 | Renal - Pd |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $93.98 | 2022 | |
| Vantive US Healthcare LLC | $89.09 | 2025 | Renal - Pd |
| Fresenius USA Marketing, INC. | $79.35 | 2021-2025 | Velphoro, Korsuva, Velphoro |
| Alnylam Pharmaceuticals INC. | $78.88 | 2021-2024 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.51 | 2025 | Jardiance |
| Travere Therapeutics, INC. | $65.27 | 2024-2025 | Filspari |
| Apellis Pharmaceuticals, INC. | $52.21 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $50.22 | 2022-2023 | Gattex |
| Cook Medical LLC | $44.29 | 2022-2024 | Zilver Ptx, Rosen |
| Kyowa Kirin, INC. | $35.26 | 2024-2025 | Crysvita |
| Novo Nordisk INC | $32.09 | 2023 | Ozempic |
| Scpharmaceuticals INC. | $25.43 | 2025 | |
| Ardelyx, INC. | $24.88 | 2024 | Ibsrela |
| Nuwellis, INC. | $23.57 | 2022 | |
| Horizon Therapeutics Plc | $21.24 | 2023 | Krystexxa |
| Renalytix Ai, INC. | $17.72 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $16.58 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $15.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Baynes-Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.